STRIDE-CAP

The STRIDE-CAP pilot study will precede the full STRIDE-CAP study and aims to establish the feasibility and methodological framework for the subsequent international, observational test-negative design (TND) case-control study. 

The full study will evaluate the vaccine effectiveness of an adult-specific pneumococcal conjugate vaccine within a real-world context.

Ecraid will assume responsibility for the study's operational management in Europe and the strategic selection of European study sites. The CLIN-Net team, a component of Ecraid, has successfully identified and selected 21 sites across four European nations: Spain, Italy, Germany, and the Netherlands. 

The projected participant recruitment period, spanning from April to September 2025, necessitates a rapid study execution, which Ecraid's warm-base network is ideally positioned to provide.

JULY 2025 • The first patient in the pilot has been enrolled.

JUNE 2025 • The first Site Initiation Visit has been successfully completed.

Merck Sharp & Dohme LLC will serve as the financial sponsor and study sponsor within the European Union.

IQVIA will function as the global Contract Research Organization (CRO) overseeing the study's implementation.